Literature DB >> 22078644

Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments.

Santosh Kesari1.   

Abstract

Glioblastoma (GBM) is a highly malignant brain cancer characterized by uncontrolled cellular proliferation, diffuse infiltration, a tendency for necrosis, significant angiogenesis, intense resistance to apoptosis, and widespread genomic aberrations. Prognosis is poor and treatments are largely palliative, although there are subsets of patients that have prolonged survival. Greater understanding of the tumor biology of GBM has been achieved in the past decade, leading to the prospect of novel targeted therapies and biomarker-based individualization of therapy. The goal of this review is to describe the tumor biology and pathologic features of GBM, guidelines for classification and diagnosis, the current status of prognostic and predictive biomarkers, and the role of the blood-brain barrier in delivering therapy for GBM.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22078644     DOI: 10.1053/j.seminoncol.2011.09.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  44 in total

Review 1.  Zinc and zinc-containing biomolecules in childhood brain tumors.

Authors:  Jan Hrabeta; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Sona Krizkova; Vojtech Adam
Journal:  J Mol Med (Berl)       Date:  2016-09-16       Impact factor: 4.599

2.  Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor.

Authors:  Tian Tian; Aimin Li; Hong Lu; Ran Luo; Mingzhi Zhang; Zhaoming Li
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

3.  Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Authors:  Yael Kusne; Eugenio A Carrera-Silva; Anthony S Perry; Elisabeth J Rushing; Edward K Mandell; Justin D Dietrich; Andrea E Errasti; Daniel Gibbs; Michael E Berens; Joseph C Loftus; Christopher Hulme; Weiwei Yang; Zhimin Lu; Kenneth Aldape; Nader Sanai; Carla V Rothlin; Sourav Ghosh
Journal:  Sci Signal       Date:  2014-08-12       Impact factor: 8.192

4.  Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme.

Authors:  Timothy T Cavanagh; Lisa M Holle
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

Review 5.  Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging.

Authors:  Nathan S White; Carrie McDonald; Carrie R McDonald; Niky Farid; Josh Kuperman; David Karow; Natalie M Schenker-Ahmed; Hauke Bartsch; Rebecca Rakow-Penner; Dominic Holland; Ahmed Shabaik; Atle Bjørnerud; Tuva Hope; Jona Hattangadi-Gluth; Michael Liss; J Kellogg Parsons; Clark C Chen; Steve Raman; Daniel Margolis; Robert E Reiter; Leonard Marks; Santosh Kesari; Arno J Mundt; Christopher J Kane; Christopher J Kaine; Bob S Carter; William G Bradley; Anders M Dale
Journal:  Cancer Res       Date:  2014-09-01       Impact factor: 12.701

6.  Use of genetically engineered stem cells for glioma therapy.

Authors:  Hiroki Namba; Hiroshi Kawaji; Tomohiro Yamasaki
Journal:  Oncol Lett       Date:  2015-11-04       Impact factor: 2.967

7.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

8.  Expression and prognostic value of the WEE1 kinase in gliomas.

Authors:  Darija Music; Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Jacob Hjelmborg; Karin de Stricker; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2016-01-06       Impact factor: 4.130

9.  MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.

Authors:  Marina Radoul; Myriam M Chaumeil; Pia Eriksson; Alan S Wang; Joanna J Phillips; Sabrina M Ronen
Journal:  Mol Cancer Ther       Date:  2016-02-16       Impact factor: 6.261

Review 10.  Emerging immunotherapies for glioblastoma.

Authors:  Rupen Desai; Carter M Suryadevara; Kristen A Batich; S Harrison Farber; Luis Sanchez-Perez; John H Sampson
Journal:  Expert Opin Emerg Drugs       Date:  2016-06       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.